Drug-induced and toxic myopathies

Best Practice and Research: Clinical Rheumatology

Volumn 17, Issue 6, 2003, Pages 877-907

  Guis, Sandrine ^a,b   Mattéi, Jean Pierre ^a,b   Lioté, Frédéric ^c  

^a HÔPITAL DE LA CONCEPTION   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Colchicine; Cyclosporine; Drug induced; Myopathy; Myositis; Side effects; Statins

Indexed keywords

AUROTHIOMALATE; COLCHICINE; CYCLOSPORIN A; DEXTROPROPOXYPHENE; DICLOFENAC; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GLYCYRRHIZIC ACID; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INHALATION ANESTHETIC AGENT; MENTHOL; METHOTREXATE; NEW DRUG; NIFLUMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PANTOPRAZOLE; PARACETAMOL; PENICILLAMINE; PHENELZINE; PHENYLBUTAZONE; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; STEROID; SUXAMETHONIUM; TIOPRONIN; UNINDEXED DRUG; URETHAN DERIVATIVE;

AREFLEXIA; ARM MUSCLE; ASTHMA; AUTOIMMUNE DISEASE; BIOLOGICAL WARFARE; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; DERMATOMYOSITIS; DISEASE CLASSIFICATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG OVERDOSE; DRUG OXIDATION; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSPHAGIA; EDEMA; FASCIITIS; FATIGUE; GENETIC PREDISPOSITION; GOUT; GUILLAIN BARRE SYNDROME; HEART BLOCK; HUMAN; LEG; LUPUS ERYTHEMATOSUS; LYSOSOME; LYSOSOME STORAGE DISEASE; MACROPHAGE; MALARIA; MALIGNANT HYPERTHERMIA; MUSCLE ATROPHY; MUSCLE CRAMP; MUSCLE NECROSIS; MUSCLE WEAKNESS; MYALGIA; MYASTHENIA; MYOFIBROSIS; MYOPATHY; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; NONHUMAN; PAIN; PATIENT MONITORING; POLYMYOSITIS; PRESCRIPTION; PRIORITY JOURNAL; QUADRIPLEGIA; REVIEW; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK FACTOR; SENSORIMOTOR NEUROPATHY; SENSORY DYSFUNCTION; SKIN FIBROSIS; SUBCUTANEOUS TISSUE; TENDON REFLEX; TERRORISM;

EID: 1542346427     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2003.11.002     Document Type: Review

References (186)

1. Le Quintrec JS & Le Quintrec JL. Drug-induced myopathies. Baillère's Clinical Rheumatology 1991; 5: 21-38.
2. Knochel JP. Mechanisms of rhabdomyolysis. Current Opinion in Rheumatology 1993; 5: 725-731.
3. Sieb JP & Gillessen T. Latrogenic and toxic myopathies. Muscle and Nerve 2003; 27: 142-156.
4. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 2001; 291: 1304-1351.
5. Guttmacher AE & Collins FS. Genomic medicine - a primer. New England Journal of Medicine 2002; 347: 1512-1520.
6. Grant EP, Pickard MD, Briskin MJ et al. Gene expression profiles: creating new perspectives in arthritis research. Arthritis and Rheumatism 2002; 46: 874-884.
7. Evans M & Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Safety 2002; 25: 649-663.
8. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicology Letters 2002; 128: 159-168.
9. Ording H, Brancadoro V et al. Cozzolino S. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiologica Scandinavica 1997; 41: 955-966.
10. Bendahan D, Kozak-Ribbens G et al. Rodet L. Phosphorus magnetic resonance spectroscopy characterization of muscular metabolic anomalies in patients with malignant hyperthermia: application to diagnosis. Anesthesiology 1998; 88: 96-107.
11. Wittwer M, Fluck M et al. Hoppeler H. Prolonged unloading of rat soleus muscle causes distinct adaptations of the gene profile. FASEB Journal 2002; 16: 884-886.
12. Bergstrom DA, Penn BH et al. Strand A. Promoter-specific regulation of MyoD binding and signal transduction cooperate to pattern gene expression. Molecular Cell 2002; 9: 587-600.
13. Zhao P, Iezzi S, Sartorelli V et al. Slug is downstream of myoD: identification of novel pathway members via temporal expression profiling. Journal of Biological Chemistry 2002; 277: 20 091-20 101.
14. 2+ release in skinned skeletal muscle fibers. American Journal of Physiology (Cell Physiology) 2001; 281: C207-C214.
15. Hoffman EP, DuBois DC et al. Hoffman R. Expression profiling and pharmacogenomics of muscle and muscle disease. Current Opinion in Pharmacology 2003; 3: 309-316.
16. Nakai A, Nishikata M, Uchida T et al. Enhanced myopathy following administration of hypolipidemic agents under urethane anesthesia. Biological and Pharmaceutical Bulletin 1997; 20: 104-106.
17. Ikemoto T & Endo M. Properties of Ca (2 +) release induced by clofibric acid from the sarcoplasmic reticulum of mouse skeletal muscle fibres. British Journal of Pharmacology 2001; 134: 719-728.
18. Gould Rothberg BE, Sundseth SS, DiPippo VA et al. The characterization of PRAR alpha ligand drug action in an in vivo model by comprehensive differential gene expression profiling. Functional and Integrative Genomics 2001; 1: 294-304.
19. Brun S, Carmona MC, Mampel T et al. Activators of peroxisome proliferator-activated receptor-alpha induce the expression of the uncoupling protein-3 gene in skeletal muscle: a potential mechanism for the lipid intake-dependent activation of uncoupling protein-3 gene expression at birth. Diabetes 1999; 48: 1217-1222.
20. Diehl AM & Hoek JB. Mitochondrial uncoupling: role of uncoupling protein anion carriers and relationship to thermogenesis and weight control 'the benefits of losing control'. Journal of Bioenergetics and Biomembranes 1999; 31: 493-506.
21. Johnson JA. Drug target pharmacogenomics: an overview. American Journal of Phormacogenomics 2001; 1: 271-281.
22. Leventhal LJ, Kuritsky L, Ginsburg R & Bomalaski JS. Salicylate-induced rhabdomyolysis. American Journal of Emergency Medicine 1989; 7: 409-410.
23. Heng MC. Local necrosis and interstitial nephritis due to topical salicylate and menthol. Cutis 1987; 39: 442-444.
24. Havill JH. Malignant hyperthermia caused by salicylate overdose associated with phenelzine therapy - a case report. Anaesthesia and Intensive Care. 1974; 2: 380-383.
25. Moneret-Vautrin DA, Morisset M, Humbert JC et al. Acetaminophen-induced rhabdomyolysis. Allergy 1999; 54: 1115-1116.
26. Skjoto J & Reikvam A. Hyperthermia and rhabdomyolysis in self-poisoning with paracetamol and salicylates. Report of a case. Acta Medica Scandinavica 1979; 20: 473-476.
27. Molia A, Novella JL, Frances C et al. Rhabdomyolysis following therapeutic doses of oral and injectable morphine. Therapie 2002; 57: 595-597.
28. Oehler U, Sinicina I & Helpap B. Extensive bilateral lower leg muscle necrosis after nasal application of heroin. Macroscopic and histologic findings in a 23-year-old man. Der Pathologe 2002; 23: 318-320.
29. Ramachandran S, Giles PD & Hartland A. Acute renal failure due to rhabdomyolysis in presence of concurrent ciprofibrate and ibuprofen treatment. British Medical Journal 1997; 314: 1593.
30. Curran JJ & Janieson TW. Dermatomyositis-like syndrome associated with phenylbutazone therapy. Journal of Rheumatology 1987; 14: 397-398.
31. Halla JT, Hardin JG & Linn JE. Postinjection nonvasomotor reactions during chrysotherapy. Constitutional and rheumatic symptoms following injections of gold salts. Arthritis and Rheumatism 1977; 20: 1188-1191.
32. Schlumpf U, Meyer M, Ulrich J & Friede RL. Neurologic complications induced by gold treatment. Arthritis and Rheumatism 1983; 26: 825-831.
33. Chattopadhyay I, Shetty HG, Routledge PA & Jeffery J. Colchicine induced rhabdomyolysis. Postgraduate Medical Journal 2001; 77: 191-192.
34. Schiff D & Drislane FW. Rapid-onset colchicine myoneuropathy. Arthritis and Rheumatism 1992; 35: 1535-1536.
35. Doyle DR, McCurley TL & Sergent JS. Fatal polymyositis in D-penicillamine-treated rheumatoid arthritis. Annals of internal Medicine 1983; 98: 327-330.
36. Sany J, Combe B, Verdie-Petibon D et al. Long-term tolerability of tiopronin (Acadione) in the treatment of rheumatoid arthritis. A propos of 140 personal cases. Revue du Rhumatisme et des Maladies Osteoarticulaires 1990; 57: 105-111.
37. Cherasse A, Maillefert JF, Henlin JL et al. Tiopronin-induced myasthenia. Revue du Rhumatisme (English edition) 1999; 66: 238-239.
38. Katayama I & Nishioka K. Lupus like syndrome induced by 2-mercaptopropionylglycine. Journal of Dermatology 1986; 13: 151-153.
39. Preedy VR, Wassif WS, Baldwin D et al. Skeletal muscle protein loss due to D-penicillamine results from reduced protein synthesis. International Journal of Biochemistry and Cell Biology 2001; 33: 1013-1026.
40. Preedy VR, Marway JS, Baldwin D et al. Experimental D-penicillamine-induced myopathy. Biochemical Society Transplantation 1996; 24: 266S.
41. Halla JT & Hardin JG. Underrecognized postdosing reactions to methotrexate in patients with rheumatoid arthritis. Journal of Rheumatology 1994; 21: 1224-1226.
42. McKendry RJ. The remarkable spectrum of methotrexate toxicities. Rheumatic Diseases Clinics of North America 1997; 23: 939-954.
43. Troger U, Stotzel B, Martens-Lobenhoffer J et al. Drug points: severe myalgia from an interaction between treatments with pantoprazole and methotrexate. British Medical Journal 2002; 324: 1497.
44. Norden DK, Lichtenstein GR & Williams WV. Sulfasalazine-induced myopathy. American Journal of Gastroenterology 1994; 89: 801-802.
45. Gunnarsson I, Nordmark B, Hassan Bakri A et al. Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA. Rheumatology 2000; 39: 886-893.
46. Coukell AJ, Markham. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. Drugs and Aging 1998; 12: 149-168.
47. Wellington K & Goa KL. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy. Drugs 2003; 63: 417-437.
48. Maksymowych WP, Jhangri GS, Fitzgerald AA et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis and Rheumatism 2002; 46: 766-773.
49. Saway PA, Heck LW, Bonner JR & Kirklin JK. Azathioprine hypersensitivity. Case report and review of the literature. American Journal of Medicine 1988; 84: 960-964.
50. Compton MR & Crosby DL. Rhabdomyolysis with azathioprine hypersensitivity syndrome. Archives of Dermatology 1996; 132: 1254-1255.
51. Neu AM, Furth SL, Case BW et al. Evaluation of neurotoxicity in pediatric renal transplant recipients treated with tacrolimus (FK506). Clinical Transplantation 1997; 11: 412-414.
52. Maes B, Oellerich M, Ceuppens JL et al. A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis. Nephrology Dialysis Transplantation 2002; 17: 923-926.
53. Marotte H, Charrin JE & Miossec P. Infliximab-induced aseptic meningitis. Lancet 2001; 358: 1784.
54. Debandt M, Vittecoq O, Descamps V et al. Anti-TNF-alpha-induced systemic lupus syndrome. Clinical Rheumatology 2003; 22: 56-61.
55. Clark LT. Treating dyslipidemia with statins: the risk-benefit profile. American Heart Journal 2003; 145: 387-396.
56. Bolego C, Baetta R, Bellosta S et al. Safety considerations for statins. Current Opinion in Lipidology 2002; 13: 637-644.
57. Thompson PD, Clarkson P & Karas RH. Statin-associated myopathy. Journal of the American Medical Association 2003; 289: 1681-1690.
58. Omar MA, Wilson JP & Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Annals of Phormacatherapy 2001; 35: 1096-1107.
59. Baker SK & Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clinical and Investigative Medicine 2001; 24: 258-272.
60. Omar MA & Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Annals of Pharmacotherapy 2002; 36: 288-295.
61. Phillips PS, Haas RH, Bannykh S et al. Statin-associated myopathy with normal creatine kinase levels. Annals of Internal Medicine 2002; 137: 581-585.
62. Farnier M, Bortolini M, Salko T et al. Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil). American Journal of Cardiology 2003; 91: 238-240.
63. Kind AH, Zakowski LJ & McBride PE. Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction. Wisconsin Medical Journal 2002; 101: 53-56.
64. Flint OP, Masters BA, Gregg RE & Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicology and Applied Pharmacology 1997; 145: 91-98.
65. Martin J & Krum H. Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant? Drug Safety 2003; 26: 13-21.
66. Prueksaritanont T, Subramanian R, Fang X et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metabolism and Dispostition 2002; 30: 505-512.
67. Guis S, Bendahan D, Kozak-Ribbens G et al. Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility. Arthritis and Rheumatism 2003; 49: 237-238.
68. Duriez P. Mechanisms of actions of statins and fibrates. Therapie 2003; 58: 5-14.
69. Lavarenne J & Poinas-Caillaud H. Muscular involvement and fibrates. Analysis of databanks of the French System of Pharmacovigilance. Therapie 1991; 46: 347-349.
70. Sauvaget F, Piette JC, Herson S et al. Fenofibrate induced polymyositis. Revue de Medecine Interne 1991; 12: 52-54.
71. Rush P, Baron M & Kapusta M. Clofibrate myopathy: a case report and a review of the literature. Seminars in Arthritis and Rheumatism 1986; 15: 226-229.
72. Shek A & Ferrill MJ. Statin-fibrate combination therapy. Annals of Pharmacotherapy 2001; 35: 908-917.
73. Tomlinson B, Chan P & Lan W. How well tolerated are lipid-lowering drugs? Drugs Aging 2001; 18: 665-683.
74. Federman DG, Hussain F & Walters AB. Fatal rhabdomyolysis caused by lipid-lowering therapy. Southern Medical Journal 2001; 94: 1023-1026.
75. Kind AH, Zakowski LJ & McBride PE. Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction. Wisconsin Medical Journal 2002; 101: 53-56.
76. Schlienger JL, Goichot B, Grunenberger F & Pradignac A. Thyroid myopathy disclosed by a fibrate. Revue de Medecine Interne 1997; 18: 169-170.
77. Fredenrich A, Sadoul JL, Jambou P & Vinti H. Rhabdomyolysis with acute renal insufficiency: role of the association of fibrate and hypothyroidism. Revue de Medecine Interne 1991; 12: 238.
78. Clouatre Y, Leblanc M, Ouimet D & Pichette V. Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism. Nephrology, Dialysis, Transplantation 1999; 14: 1047-1048.
79. Litin SC & Anderson CF. Nicotinic acid-associated myopathy: a report of three cases. American Journal of Medicine 1989; 86: 481-483.
80. Gharavi AG, Diamond JA, Smith DA & Phillips RA. Niacin-induced myopathy. American Journal of Medicine 1994; 74: 841-842.
81. Goldstein MR. Nicotinic acid-associated myopathy. American Journal of Medicine 1989; 87: 248.
82. Ballantyne CM, Corsini A, Davidson MH et al. Risk for myopathy with statin therapy in high-risk patients. Archives of Internal Medecine. 2003; 163: 553-564.
83. Bays HE, Dujovne CA, McGovern ME et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ ADVOCATE]). American Journal of Cardiology 2003; 91: 667-672.
84. Misra VP. The changed image of botulinum toxin. British Medical Journal 2002; 325: 1188.
85. Cherington M. The clinical spectrum of botulism. Muscle and Nerve 1998; 21: 701-710.
86. Maselli R. Pathogenesis of human botulism. Annals of the New York Academy of Sciences 1998; 841: 122-139.
87. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle and Nerve 1997; 6: S146-S168.
88. Schantz EJ & Johnson EA. Dose standardisation of botulinum toxin. Lancet 1990; 335: 421.
89. Bakheit AM, Ward CD & McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. Journal of Neurology, Neurosurgery and Psychiatry 1997; 62: 198.
90. Mezaki T, Kaji R, Kohara N & Kimura J. Development of general weakness in a patient with amyotrophic lateral sclerosis after focal botulinum toxin injection. Neurology 1996; 46: 845-846.
91. Khan MA. Effects of myotoxins on skeletal muscle fibers. Progress in Neurobiology 1995; 46: 541-560.
92. Eyrich K, Agostini B, Schulz A et al. Clinical and morphological observations of skeletal muscle changes in tetanus. Deutsche Medizinische Wochenschrift 1967; 24: 530-540.
93. Asa DK, Bertorini TE & Pinals RS. Myositis ossificans circumscripta: a complication of tetanus. American Journal of the Medical Sciences 1986; 292: 40-43.
94. Tang WM, Wong JW, Wong LL & Leong JC. Streptococcal necrotizing myositis: the role of magnetic resonance imaging. A case report. Journal of Bone and Joint Surgery (Am) 2001; 83: 1723-1726.
95. Khandekar JD. Organophosphate poisoning. Journal of the American Medical Association 1971; 217: 1864.
96. Namba T, Nolte CT, Jackrel J & Grob D. Acute and chronic manifestations poisoning due to organophosphate insecticides. American Journal of Medicine 1971; 50: 475-492.
97. Ahlgren JD, Manz HJ & Harvey JC. Myopathy of chronic organophosphate poisoning: a clinical entity? Southern Medical Journal 1979; 72: 555-558. see also 563.
98. Ochi G, Watanabe K, Tokuoka H et al. Neuroleptic malignant-like syndrome: a complication of acute organophosphate poisoning. Canadian Journal of Anaesthesia 1995; 42: 1027-1030.
99. Futagami K, Hirano N, Iimori E et al. Severe fenitrothion poisoning complicated by rhabdomyolysis in psychiatric patient. ACTA Medical Okayama 2001; 55: 129-132.
100. van den Neucker K, Vanderstraeten G, De Muynck M & De Wilde V. The neurophysiologic examination in organophosphate ester poisoning. Case report and review of the literature. Electromyography and Clinical Neurophysiology 1991; 31: 507-511.
101. Fukuhara N, Hoshi M & Mori S. Core/targetoid fibres and multiple cytoplasmic bodies in organophosphate neuropathy. Acta Neurapathologica 1977; 40: 137-144.
102. Cavaliere MJ, Puga FR, Calore EE et al. Protective effect of pralidoxime on muscle fiber necrosis induced by organophosphate compounds. Journal of Toxicology. (Clinical Toxicology) 1998; 36: 295-300.
103. Spiller HA & Bosse GM. Prospective study of morbidity associated with snakebite envenomation. Journal of Toxicology (Clinical Toxicology) 2003; 41: 125-130.
104. Mebs D & Ownby CL. Myotoxic components of snake venoms: their biochemical and biological activities. Pharmacology and Therapeutics 1990; 48: 223-236.
105. Warnell DA:. Clinical toxicology of snakebite in Africa and the Middle East and Asia. In Jung Meier (ed.) Clinical Toxicology of Animal Venoms and Poisons. Boca Raton: CRC Press, 1995, pp 433-594.
106. Bush SP & Jansen PW. Severe rattlesnake envenomation with anaphylaxis and rhabdomyolysis. Annals of Emergency Medicine 1995; 25: 845-848.
107. Jolles S, Lawrence S, Gallagher J & Fulcher D. Severe rhabdomyolysis after tiger snake bite. Journal of the Royal Society of Medicine 1998; 91: 267-268.
108. Rossi MA, Peres LC, de Paola F et al. Electron-microscopic study of systemic myonecrosis due to poisoning by tropical rattlesnake (Crotalus durissus terrificus) in humans. Archives of Pathology and Laboratory Medicine 1989; 113: 169-173.
109. Mebs D & Langeluddeke T. European viper venoms: haemorrhagic and myotoxic activities. Toxicon 1992; 30: 1303-1306.
110. Binder LS. Acute arthropod envenomation. Incidence, clinical features and management. Medical Toxicology Adverse Drug Experiment 1989; 4: 163-173.
111. Muller GJ. Black and brown widow spider bites in South Africa. A series of 45 cases. South African Medical Journal 1993; 83: 399-405.
112. Gala S & Katelaris CH. Rhabdomyolysis due to redback spider envenomation. Medical Journal of Australia 1992; 157: 66.
113. Vetter RS, Visscher PK & Camazine S. Mass envenomations by honey bees and wasps. Westem Journal of Medicine 1999; 170: 223-227.
114. Franca FO, Benvenuti LA, Fan HW et al. Severe and fatal mass attacks by 'killer' bees (Africanized honey bees - Apis mellifera scutellata) in Brazil: clinicopathological studies with measurement of serum venom concentrations. Quarterly Journal of Medicine 1994; 87: 269-282.
115. Gillespie NC, Lewis RJ, Pearn JH et al. Ciguatera in Australia. Occurrence, clinical features, pathophysiology and management. Medical Journal of Australia 1986; 145: 584-590.
116. Stommel EW, Parsonnet J & Jenkyn LR. Polymyositis after ciguatera toxin exposure. Archives of Neurology 1991; 48: 874-877.
117. Papadimitriou A, Hadjigeorgiou GM, Tsairis P et al. Myoglobinuria due to quail poisoning. European Neurology 1996; 36: 142-145.
118. Rizzi D, Basile C, Di Maggio A et al. Clinical spectrum of accidental hemlock poisoning: neurotoxic manifestations, rhabdomyolysis and acute tubular necrosis. Nephrology, Dialysis, Transplantation 1991; 6: 939-943.
119. Dalakas MC, IIIa I, Pezeshkpour GH et al. Mitochondrial myopathy caused by long-term zidovudine therapy. New England Journal of Medicine 1990; 19: 1098-1105.
120. Butori C, Desnuelle C, Hofman P et al. Muscular involvement in the course of AIDS. Anatomo-clinical study of 17 cases. Annals of Pathology 1995; 15: 424-430.
121. Semino-Mora MC, Leon-Monzon ME & Dalakas MC. The effect of L-carnitine on the AZT-induced destruction of human myotubes. Part II: Treatment with L-carnitine improves the AZT-induced changes and prevents further destruction. Laboratory Investigation 1994; 71: 773-781.
122. Gold R, Meurers B & Reichmann H. Mitochondrial myopathy caused by long-term zidovudine therapy. New England Journal of Medicine 1990; 4: 994.
123. Dalakas MC. Peripheral neuropathy and antiretroviral drugs. Journal of the Peripheral Nervous System 2001; 6: 14-20.
124. Cazzalini O, Lazze MC, Iamele L et al. Early effects of AZT on mitochondrial functions in the absence of mitochondrial DNA depletion in rat myotubes. Biochemical Pharmacology 2001; 1: 893-902.
125. Masini A, Scotti C, Calligaro A et al. Zidovudine-induced experimental myopathy: dual mechanism of mitochondrial damage. Journal of the Neurological Sciences 1991; 166: 131-140.
126. Sinnwell TM, Sivakumar K, Soueidan S et al. Metabolic abnormalities in skeletal muscle of patients receiving zidovudine therapy observed by 31P in vivo magnetic resonance spectroscopy. Journal of Clinical Investigation 1995; 96: 126-131.
127. Breil M & Chariot P. Muscle disorders associated with cyclosporin treatment. Muscle and Nerve 1999; 22: 1631-1636.
128. Chassagne P, Mejjad O, Moore N et al. Myopathy as possible side-effect of cyclosporin. Lancet 1989; 2(4): 1104.
129. Larner AJ, Sturman SG, Hawkins JB & Anderson M. Myopathy with ragged red fibres following renal transplantation: possible role of cyclosporin-induced hypomagnesaemia. Acta Neuropathologica 1994; 88: 189-192.
130. Stratton JR, Kemp GJ, Daly RC et al. Effects of cardiac transplantation on bioenergetic abnormalities of skeletal muscle in congestive heart failure. Circulation 1994; 89: 1624-1631.
131. Noppen M, Velkeniers B, Dierckx R et al. Cyclosporin and myopathy. Annals of Internal Medicine 1987; 107: 945-946.
132. Ducloux D, Schuller V, Bresson-Vautrin C & Chalopin JM. Colchicine myopathy in renal transplant recipients on cyclosporin. Nephrology, Dialysis, Transplantation 1997; 12: 2389-2392.
133. Caglar K, Safali M, Yavuz I et al. Colchicine-induced myopathy with normal creatine phosphokinase level in a renal transplant patient. Nephron 2002; 92: 922-924.
134. Yamada H, Kotaki H, Sawada Y & Iga T. Simvastatin-tacrolimus and simvastatin-cyclosporin interactions in rats. Biopharmaceutic and Drug Disposition 1998; 19: 279-284.
135. Kusus M, Stapleton DD, Lertora JJ et al. Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions. American Journal of the Medical Sciences 2000; 320: 394-397.
136. Stein M, Bell MJ & Ang LC. Hydroxychloroquine neuromyotoxicity. Journal of Rheumatology 2000; 27: 2927-2931.
137. Richards AJ. Hydroxychloroquine myopathy. Journal of Rheumatology 1998; 25: 1642-1643.
138. Sghirlanzoni A, Mantegazza R, Mora M et al. Chloroquine myopathy and myasthenia-like syndrome. Muscle and Nerve 1988; 11: 114-119.
139. Rollof J & Vinge E. Neurologic adverse effects during concomitant treatment with ciprofloxacin, NSAIDs, and chloroquine: possible drug interaction. Annals of Pharmacotherapy 1993; 27: 1058-1059.
140. Estes ML, Ewing-Wilson D, Chou SM et al. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. American Journal of Medicine 1987; 82: 447-455.
141. Murakami N, Oyama F, Gu Y et al. Accumulation of tan in autophagic vacuoles in chloroquine myopathy. Journal of Neuropathology and Experimental Neurology 1998; 57: 664-673.
142. Kumamoto T, Araki S, Watanabe S et al. Experimental chloroquine myopathy: morphological and biochemical studies. European Neurology 1989; 29: 202-207.
143. Oyama F, Murakami N & Ihara Y. Chloroquine myopathy suggests that tau is degraded in lysosomes: implication for the formation of paired helical filaments in Alzheimer's disease. Neuroscience Research 1998; 31: 1-8.
144. Kumamoto T, Nagao SI, Sugihara R et al. Effect of chloroquine-induced myopathy on rat soleus muscle sarcoplasm and expression of clathrin. Muscle and Nerve 1998; 21: 665-668.
145. Roth RF, Itabashi H, Louie J et al. Amiodarone toxicity: myopathy and neuropathy. American Heart Journal 1990; 119: 1223-1225.
146. Carella F. Myopathy and accumulation of amiodarone. Muscle and Nerve 1989; 12: 514.
147. Bonnet C, Zabraniecki L, Bertin P et al. Amiodarone-induced neuromyopathy mimicking polymyositis. Revue du Rhumatism (English edition) 1995; 62: 468.
148. Clouston PD & Donnelly PE. Acute necrotising myopathy associated with amiodarone therapy. Australian and New Zealand Journal of Medicine 1989; 19: 483-485.
149. Costa-Jussa FR, Guevara A, Brook GA et al. Changes in denervated skeletal muscle of amiodarone-fed mice. Muscle and Nerve 1988; 11: 627-637.
150. Fardeau M, Tome FM & Simon P. Muscle and nerve changes induced by perhexiline maleate in man and mice. Muscle and Nerve 1979; 2: 24-36.
151. Tomlinson IW & Rosenthal FD. Proximal myopathy after perhexiline maleate treatment. British Medical Journal 1977; 1: 1319-1320.
152. Sobh M, Refaie A, El-Tantawy AE et al. Study of neuromyopathy in amyloid kidney transplant recipients. American Journal of Nephrology 1996; 16: 114-117.
153. Posada de la Paz M, Philen RM & Borda AI. Toxic oil syndrome: the perspective after 20 years. Epidemiological Reviews 2001; 23: 231-247.
154. Philen RM & Posada M. Toxic oil syndrome and eosinophilia-myalgia syndrome: May 8-10, 1991, World Health Organization meeting report. Seminars in Arthritis and Rheumatism 1993; 23: 104-124.
155. Valenciano L, Munoz E, Larraga V et al. Spanish 'toxic-oil' syndrome. Nature 1983; 7: 472.
156. Pellissier JF, Figarella-Branger D & Serratrice G. Neuromuscular diseases with eosinophilia. Médecine Tropicale 1998; 58: 471-476.
157. Mateo IM, Izquierdo M, Fernandez-Dapica MP et al. Toxic epidemic syndrome: musculoskeletal manifestations. Journal of Rheumatology 1984; 11: 333-338.
158. Bell SA. The toxic oil syndrome: an example of an exogenously induced autoimmune reaction. Toxic oil syndrome molecular. Biology Reports 1996; 23: 261-263.
159. Hard GC. A search for an animal model of the Spanish toxic oil syndrome. Food and Chemical Toxicology 2002; 40: 1551-1567.
160. Eidson M, Philen RM, Sewell CM et al. Tryptopha, and eosinophilia-myalgia syndrome in New Mexico. Lancet 1990; 335: 645-648.
161. Blackburn Jr WD. Eosinophilia myalgia syndrome. Seminars in Arthritis and Rheumatism 1997; 26: 788-793.
162. Mayeno AN, Lin F, Foote CS et al. Characterization of 'peak E', a novel amino acid associated with eosinophilia-myalgia syndrome. Science 1990; 250: 1707-1708.
163. Spitzer WO, Haggerty JL, Berkson L et al. Analysis of centers for disease control and prevention criteria for the eosinophilia-myalgia syndrome in a geographically defined population. Journal of Rheumatology 1996; 46: 73-80.
164. Kaufman LD. Chronicity of the eosinophilia-myalgia syndrome. A reassessment after three years. Arthritis and Rheumatism 1994; 37: 84-87.
165. Hertzman PA. Criteria for the definition of the eosinophilia-myalgia syndrome. Journal of Rheumatology 1996; 46: 7-12.
166. Silver RM, Heyes MP, Maize JC et al. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. New England Journal of Medicine 1990; 322: 874-881.
167. Clauw DJ, Hewes B, Nelson MP-31 et al. magnetic resonance spectroscopy of skeletal muscle in the eosinophilia-myalgia syndrome: a preliminary study. Journal of Rheumatology 1994; 21: 654-657.
168. Gross B, Ronen N, Honigman S et al. Tryptophan toxicity - time and dose response in rats. Advances in Experimental Medicine and Biology 1999; 467: 507-516.
169. Gherardi RK, Coquet M, Chérin P et al. Macrophagic myofasciitis: an emerging entity. Lancet 1998; 352: 347-352.
170. Gherardi RK, Coquet M, Chérin P et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 2001; 124: 1821-1831.
171. Authier FJ, Cherin P, Creange A et al. Central nervous system disease in patients with macrophagic myofasciitis. Brain 2001; 124: 974-983.
172. Guis S, Mattei JP, Nicoli F et al. Identical twins with macrophagic myofasciitis: genetic susceptibility and triggering by aluminic vaccine adjuvants? Arthritis and Rheumatism 2002; 45: 543-545.
173. Guis S, Pellissier JF, Nicoli F et al. HLA DRB1*01 and macrophagic myofasciitis. Arthritis and Rheumatism 2002; 46: 2535-2537.
174. Papo T. Macrophagic myofasciitis: focal or systemic? Joint Bone Spine 2003; 70: 242-245.
175. Gherardi RK. Lesson from macrophagic myofasciitis: towards definition of a vaccine adjuvant-related syndrome. Revue Neurologique 2003; 159: 162-164.
176. Hodak E, Gadoth N, David M & Sandbank M. Muscel damage induced by isotretinoin. British Medical Journal 1986; 293: 425-426.
177. Hodak E, David M, Gadoth N & Sandbank M. Etretinate-induced skeletal muscle damage. British Journal of Dermatology 1987; 116: 6263-6266.
178. Lee CT, Wu MS, Lu K & Hsu KT. Renal tubular acidosis, hypokalemic paralysis, rhabdomyolysis, and acute renal failure - a rare presentation of Chinese herb nephropathy. Renal Failure 1999; 21: 227-230.
179. Stevinson C, Huntley A & Ernst E. A systematic review of the safety of kava extract in the treatment of anxiety. Drug Safety 2002; 25: 251-261.
180. Scroggie DA, Harris M & Sakai L. Rhabdomyolysis associated with nutritional supplement use. Journal of Clinical Rheumatology 2000; 6: 328-332.
181. Hutchinson TA. Causality assessment of suspected adverse drug reactions. In Stephens MDB (ed.) Detection of New Adverse Drug Reactions, 3rd. Basingstoke: Macmillan Publishers Ltd, 1992.
182. Haramburu F, Miremont-Salamé G & Macquin K. Effets indésirables des medicaments: définitions et imputabilité. Revue du Rhumatisme 2002; 69: 346-348.
183. Kramer MS, Leventhal JM, Hutchinson TA & Feinstein AR. An algorythm for the operational assessment of adverse drug reactions. I. Background, description, and instruction for use. Journal of the American Medical Association 1979; 242: 623-632.
184. Wade OL, Adverse Reactions to Drugs, 43. London: William Heinemann Medical Books Ltd, 1970. pp. 43.
185. Lazarou J, Pomeranz BH & Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Journal of the American Medical Association 1998; 279: 1200-1205.
186. Busto U, Naranjo CA & Sellers EM. Comparison of two recently published algorithms for assessing the probability of adverse drug reactions. British Journal of Clinical Pharmacology 1982; 13: 223-227.